LBPH241115C35000
- 24.50
- 0.000.00%
Longboard Pharmaceuticals Newsroom
Express News | Longboard Pharmaceuticals Initiates Phase 3 Deep Ocean Study Evaluating Bexicaserin in Developmental and Epileptic Encephalopathies (Dees)
Longboard Pharmaceuticals Initiates Phase 3 DEEp OCEAN Study Evaluating Bexicaserin in Developmental and Epileptic Encephalopathies (DEEs)
Truist Financial Maintains Longboard Pharmaceuticals(LBPH.US) With Hold Rating
Longboard Pharmaceuticals Advances Neurological Treatments
Longboard Pharmaceuticals | 10-Q: Quarterly report
Express News | Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
Express News | Longboard Pharmaceuticals Q3 Net Income USD -24.54 Million
Oklo, CleanSpark And Wolfspeed Are Among Top 7 Mid Cap Gainers Last Week (Oct 14-18): Are The Others In Your Portfolio?
M&A Deals Roundup: Expedia, Sanofi, Zuora, Forward Air and More
Longboard Pharmaceuticals Cut to Neutral From Buy by HC Wainwright & Co.
H.C. Wainwright Maintains Longboard Pharmaceuticals(LBPH.US) With Buy Rating, Cuts Target Price to $60
Truist Financial Upgrades Longboard Pharmaceuticals(LBPH.US) to Buy Rating, Maintains Target Price $60
Strong Valuation and Strategic Acquisition Drive Buy Rating for Longboard Pharmaceuticals
Longboard Set to Be Acquired by Lundbeck for $2.6B, Stock Soars 52%
Longboard Pharmaceuticals Price Target Maintained With a $60.00/Share by Truist Securities
A Quick Look at Today's Ratings for Longboard Pharmaceuticals(LBPH.US), With a Forecast Between $60 to $60
Express News | Longboard Pharmaceuticals: If Deal Is Terminated Under Some Circumstances, Co Required to Pay H. Lundbeck A/S Termination Fee of $86.1 Mln
Baird Downgrades Longboard Pharmaceuticals to Neutral From Outperform, Price Target Is $60
Express News | Longboard Pharmaceuticals Inc : Truist Securities Cuts to Hold From Buy
ALERT: Rowley Law PLLC Is Investigating Proposed Acquisition of Longboard Pharmaceuticals, Inc.